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Tubuloglomerular feedback 
responses of the downstream 
efferent resistance: Unmasking a 
role for adenosine?
RC Blantz1,2 and V Vallon1–3
This Commentary aims to integrate or interrelate the available in vivo 
data with the in vitro study by Ren and co-workers, which comes to 
the somewhat surprising conclusion that tubuloglomerular feedback 
activation vasodilates the efferent arteriole by an adenosine-dependent 
mechanism.
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Blood fl ow and glomerular fi ltration rate 
are highly regulated in the kidney by sev-
eral factors: (1) a balance of neurohor-
monal vasodilator and vasoconstrictor 
molecules, (2) an effi  cient autoregulation 
of blood fl ow in response to variations in 
systemic blood pressure, and (3) activity 
of the tubuloglomerular feedback (TGF) 
system. Th e critical vascular resistances 
that participate in the tight control of 
blood fl ow and glomerular fi ltration rate 
have been fairly well defi ned in the case 
of hormonal and neural infl uences. Auto-
regulation to variations in blood pressure 
has been primarily localized to the aff er-
ent arteriole and preglomerular vascular 
resistances, and there is little doubt that 
the primary site for the eff ector response 
of TGF resides within the aff erent arte-
riole. However, the specifi c response of 
the eff erent arteriole has been less well 
defi ned. Ren and co-workers1 (this issue) 
now supply valuable information regard-
ing in vitro activation of TGF in a prepa-
ration with simultaneous microperfusion 
of the macula densa segment and the 
eff erent arteriole. Th eir studies come to 
the somewhat surprising conclusion that 
TGF activation (in addition to aff erent 
arteriolar vasoconstriction) vasodilates 
the eff erent arteriole, the latter being also 
the consequence of TGF-induced adeno-
sine generation and activity.2 Th ese results 
are not parochial and irrelevant to clinical 
nephrology, as maintenance of glomerular 
fi ltration rate under a variety of conditions 
is best understood if we understand the 
vascular contributions of TGF in detail, 
which include the behavior of both arteri-
oles, together constituting approximately 
80% of renal vascular resistance. To a 
great extent, the magnitude of the changes 
in resistance and the ratio of changes in 
aff erent (RA) and eff erent (RE) arteriolar 
resistances dictate the capacity to main-
tain glomerular capillary hydraulic pres-
sure (PGC) and glomerular plasma fl ow, 
both critical determinants of glomerular 
ultrafi ltration.
In normal in vivo conditions, how does 
the eff erent arteriole behave in relation-
ship to associated changes in the aff erent 
arteriole? Th ere are actually considerable 
data on this issue. We and others, using 
measurements of glomerular hemo-
dynamics, have examined the changes 
in RE in association with RA changes 
and have found a remarkable parallel-
ism in the directional changes in the 
resistances.3 Th ere are a very few physi-
ologic and pathophysiologic exceptions 
to this general relationship. In multiple 
studies, vasoconstrictors such as adrener-
gic nerves or angiotensin II and vasodila-
tors such as prostaglandins or nitric oxide 
generally demonstrated parallel eff ects on 
RA and RE, resulting in a trend for PGC to 
remain relatively constant across a wide 
range of glomerular fl ows and resistances, 
such that filtration fraction remained 
relatively stable. Administration of ben-
zolamide, a carbonic anhydrase inhibitor 
that inhi bits proximal reabsorption, may 
induce whole-kidney activation of TGF. 
We found that benzolamide induced 
largely parallel increases in RA and RE, 
constancy of glomerular capillary pres-
sure, and a fl ow-dependent reduction in 
single-nephron glomerular fi ltration rate 
(SNGFR).4 Considering the overall impact 
of the TGF system, the current results of 
Ren and co-workers1 seem somewhat 
surprising and deserve further analysis of 
studies using TGF-specifi c regulation of 
RA and RE.
Despite the overall interest in TGF 
mechanisms, few studies have attempted 
to localize the sites of the TGF eff ector by 
directly assessing aspects of glomerular 
hemodynamics during microperfusion of 
Henle’s loop in vivo. Some of these studies 
are not in complete agreement with regard 
to the responses in PGC during TGF acti-
vation, and together the available studies 
provided no defi nitive answer as to the 
role of the eff erent arteriole. In a study in 
hydropenic rats, Ichikawa5 observed that 
directly measured PGC did not change, 
whereas SNGFR decreased in response to 
TGF activation. Ichikawa concluded that 
the reduction in SNGFR was due to parallel 
increases in both RA and RE and possibly a 
reduction in the ultrafi ltration coeffi  cient.5 
Briggs and Wright6 concluded that the 
eff ector response of TGF resulted prima-
rily from aff erent arteriolar constriction, in 
part due to the observed major reductions 
in PGC during TGF activation. RE was not 
determined in that study, but the authors 
estimated its potential role in TGF by relat-
ing the range of possible values for fi ltra-
tion fraction to possible changes in RA and 
RE. Th ey concluded that the results gave no 
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indication that the observed TGF-induced 
changes in PGC and SNGFR depend on a 
net change in eff erent resistance, but they 
suggested that more direct measurements 
be taken in order to answer this question 
more certainly.6 The studies described 
above examined the TGF responses at 
only very low and maximal TGF signals. 
A study from our laboratory by Th omson 
et al. examined both the vasodilatory and 
the vasoconstrictor sides of TGF, measur-
ing online tubular fl ow rate and PGC in 
response to modest additions and subtrac-
tions of fl uid from free-fl owing nephrons.7 
Th ese closed-loop assessments concluded 
that the TGF responses were asymmetric: 
small perturbations from the operating 
point lowered or increased SNGFR by 
parallel increases or decreases in RA and 
RE, such that PGC was unchanged, indi-
cating that TGF-induced SNGFR changes 
were entirely the consequence of changes 
in nephron plasma fl ow. In contrast, rais-
ing the TGF stimulus signifi cantly above 
normal fl ow rates lowered both SNGFR 
and PGC, a response that could be per-
fectly explained by further aff erent arteri-
olar constriction in the absence of further 
increases in RE, although an actual reduc-
tion in the latter was not ruled out. In 
summary, none of the published in vivo 
single-nephron studies observed convinc-
ing evidence or required net eff erent arte-
riolar vasodilation to explain the observed 
TGF-induced reductions in SNGFR, but 
a possible contribution of an efferent 
vasodilating infl uence in response to large 
increases in the TGF signal could not be 
absolutely ruled out.
It may be possible to integrate or inter-
relate all of these seemingly disparate 
fi ndings when one considers the diff er-
ent experimental conditions. Because 
the preparation by Ren and co-workers1 
is in a bath, the normal pressure volume 
constraints and the local hormonal milieu 
may differ substantially from those in 
the glomerular arterioles and connected 
tubule in vivo. Moreover, the basal sta-
tus of the eff erent arteriole may have an 
important conditioning infl uence on the 
magnitude and even the direction of the 
response. Th is seems to be the case dur-
ing autoregulation, whereby the eff erent 
arteriole may vasodilate initially and then 
vasoconstrict with progressive reduc-
tions in systemic blood pressure.8 Studies 
from our laboratory examined the TGF 
responses of SNGFR and glomerular cap-
illary pressure in normal rats and during 
simultaneous blockade of angiotensin II 
and prostaglandin activities.9 In normal 
rats, increasing late proximal perfusion 
decreased SNGFR and PGC, although the 
turning point for pressure changes always 
appeared at higher fl ows. Aft er blockade, 
the SNGFR response remained intact, 
but no changes in PGC were observed. 
Th is we attributed to the eff erent arteri-
olar vasodilation achieved aft er combined 
hormonal blockade, leading to additional 
vasoconstrictor reserve of the efferent 
arteriole, which allowed for maintenance 
of PGC. In the in vitro study by Ren and 
co-workers,1 prior vasoconstriction with 
norepinephrine could have changed the 
baseline conditions, which in turn may 
limit capacities for vasoconstriction, bias-
ing toward a vasodilatory response, and 
unmasking the vasodilatory infl uence of 
adenosine on the eff erent arteriole during 
TGF activation.
The efferent arteriole resides within 
the mesangium at the confl uence of the 
glomerular capillaries and could func-
tion as a passive waterfall resistor, the 
resistance of which varies inversely with 
the pressure gradient from glomeru-
lar capillary to mesangial interstitium. 
A primary increase in RA, mediated by 
TGF, would immediately dissipate this 
gradient because of reductions in intra-
luminal glomerular pressure, tending to 
collapse the eff erent arteriole and thereby 
producing an increase in RE.
7 In this way, 
TGF could effect changes in RE in the 
absence of direct humoral communication 
between the macula densa and eff erent 
arteriole. Because of the study design, this 
parallel linkage of changes in RA and RE 
was excluded in the current study, which 
also may have unmasked the vasodilat-
ing infl uence of adenosine on the eff erent 
arteriole during TGF activation, and this 
may have been further facilitated by the 

















Figure 1 | Asymmetry of tubuloglomerular feedback effector response: potential role 
of an efferent vasodilatory influence of adenosine. See text for details. A1R, adenosine A1 
receptor; A2R, adenosine A2 receptor; aff, afferent arteriole; eff, efferent arteriole; [Na-K-Cl] MD, 
tubuloglomerular feedback signal at macula densa; PGC, glomerular capillary hydraulic pressure; 
RA, afferent arteriolar resistance; RE, efferent arteriolar resistance; SNGFR, single-nephron 
glomerular filtration rate.
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On the basis of the outlined in vivo 
studies, the current study by Ren and co-
workers,1 and the established vascular 
renal effects of adenosine,10 a concept 
could be envisioned in which small pertur-
bations of the TGF signal from the operat-
ing point trigger parallel changes in local 
adenosine concentrations that induce pri-
marily aff erent arteriolar vasoconstriction 
via adenosine A1 receptors and eff erent 
vasoconstriction due to passive interac-
tions with RA (see above) and/or due to 
some coactivation of adenosine A1 recep-
tors on the eff erent arteriole such that PGC 
remains unchanged. In comparison, more 
excessive TGF signals trigger larger local 
adenosine concentrations that in addition 
induce a vasodilating influence on the 
eff erent arteriole via adenosine A2 recep-
tors, which attenuates or prevents a further 
rise in RE and thus lowers PGC (Figure 1).
In summary, the basal conditions, the 
co-response of the afferent arteriole, 
and the strength of TGF stimuli applied 
may dictate the net magnitude and even 
the direction of the efferent arteriolar 
response. Th e study by Ren and co-work-
ers1 has defi ned an important infl uence, 
which tends to reduce RE during TGF 
activation, and this appears to be another 
important eff ect of local adenosine. From 
a teleological standpoint, a TGF-induced 
adenosine-mediated eff erent vasodilatory 
infl uence would be appealing especially in 
deep nephrons, where the postglomeru-
lar blood fl ow is nutritive for the medulla 
and thus consistent with a proposed role 
of adenosine in metabolic control of kid-
ney function.10
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Diabetes: Caught in the Akt?
PM Price1
One complication of diabetes is a pronounced renal cellular 
hypertrophy, inevitably resulting in chronic fibrotic changes. Chuang 
and colleagues demonstrate that hypertrophy in vitro is dependent 
on an increased phosphoinositide 3-kinase (PI3K) activity and is 
correlated with increased levels of p21WAF1/Cip1, a cell-cycle regulator 
that was previously associated with renal fibrosis and sclerosis from 
nondiabetic causes.
Kidney International (2007) 71, 839–841. doi:10.1038/sj.ki.5002200
Th e response of hypertrophy occurs in 
organs, such as heart, lungs, and kid-
neys, usually in reaction to a demand for 
increased work load. This reaction, in 
which there is an increase in total cell vol-
ume without a similar increase in total cell 
number, has been suggested in older liter-
ature to be maladaptive.1 Renal hypertro-
phy is found in several diff erent disorders 
and is associated with a progressive loss of 
kidney function and eventual glomerular 
and tubulointerstitial fi brosis. Although 
hypertrophy may be accompanied or 
preceded by a period of hyperplasia,2–4 
chronic fi brotic changes in the kidney are 
preceded by hypertrophic growth.5 Several 
in vivo models, such as the rodent models 
of streptozotocin-induced diabetes and 
renal ablation, mimic clinically observed 
kidney and systemic changes. A similar 
hypertrophic response was also observed 
in vitro when kidney cells were cultured in 
high-glucose-containing medium.6–8
The commitment to hypertrophic 
growth by kidney cells in reaction to 
diabetes or ablation has recently been 
approached by the use of gene knockout 
studies. Early evidence had shown that 
proteins associated with cell-cycle regu-
lation and inhibition were increased in 
the kidney aft er both acute and chronic 
stress,9,10 and that these inhibitors, trans-
duced into kidney proximal tubular 
cells, caused hypertrophy.11 In knock-
out models of one of these proteins, the 
p21 cyclin-dependent kinase inhibitor, 
hypertrophy, glomerulosclerosis, and 
interstitial fi brosis did not develop aft er 
partial renal ablation,4 and glomerular 
hypertrophy did not occur in streptozo-
tocin-treated mice.12 Th us it may be con-
cluded that the hyperplastic increase in 
kidney cells observed in these models was 
not detrimental, but that hypertrophic 
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